These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 11735678

  • 1. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL, Hurst M.
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [Abstract] [Full Text] [Related]

  • 3. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
    Coukell AJ, Noble S, Faulds D.
    Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
    [Abstract] [Full Text] [Related]

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001 Apr; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC, Evans WK.
    Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
    [Abstract] [Full Text] [Related]

  • 6. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [Abstract] [Full Text] [Related]

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Dec; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
    Evans WK, Le Chevalier T.
    Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B.
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
    [Abstract] [Full Text] [Related]

  • 15. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL, Bhalla S, Laranjeira L, Guerreiro M.
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [Abstract] [Full Text] [Related]

  • 16. The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis.
    Annemans L, Giaccone G, Vergnenègre A.
    Anticancer Drugs; 1999 Jul; 10(6):605-15. PubMed ID: 10885909
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
    Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, Winfree KB.
    Lung Cancer; 2015 Sep; 89(3):294-300. PubMed ID: 26122345
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.